Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call t ...

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Children and adolescents with primary hyperhidrosis often report an underappreciated but substantial psychosocial burden, ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

“Interchangeability of Selarsdi with Stelara will further enable increased access for US patients to more affordable treatment options and contribute to lowering health care costs, which is an ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has reported that the FDA has approved the biosimilar treatment ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Children receiving multiple antibiotic courses between birth and age 2 years may have a higher risk for some chronic conditions.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...